MicroRNA-186 inhibits cell proliferation and induces apoptosis in human esophageal squamous cell carcinoma by targeting SKP2

Laboratory Investigation

Volumn 96, Issue 3, 2016, Pages 317-324

  He, Wei ^a   Feng, Jianfang ^b   Zhang, Yan ^a   Wang, Yuanyuan ^c   Zang, Wenqiao ^c   Zhao, Guoqiang ^c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b HENAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; GLUCOSE TRANSPORTER 1; LUCIFERASE; MESSENGER RNA; MICRORNA; MICRORNA 186; PROTEIN; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; TWIST1 PROTEIN; UNCLASSIFIED DRUG; MIRN186 MICRORNA, HUMAN; S PHASE KINASE ASSOCIATED PROTEIN;

ADULT; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER STAGING; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MTT ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; GENETICS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS;

EID: 84959572901     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.134     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Sibley CR, Seow Y, Wood MJ. Novel RNA-based strategies for therapeutic gene silencing. Mol Ther 2010; 18: 466-476
3. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther 2006; 5: 2957-2962
4. Guo P, Coban O, Snead NM, et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev 2010; 62: 650-666
5. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355
6. Bartel DP. microRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233
7. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261
8. Wang D, Qiu C, Zhang H, et al. Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One 2010; 5
9. Cai J, Wu J, Zhang H, et al. Mir-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res 2013; 73: 756-766
10. Li H, Yin C, Zhang B, et al. Pttg1 promotes migration and invasion of human non-small cell lung cancer cells and is modulated by Mir-186. Carcinogenesis 2013; 34: 2145-2155
11. Cui G, Cui M, Li Y, et al. Mir-186 targets Rock1 to suppress the growth and metastasis of NSCLC cells. Tumour Biol 2014; 35: 8933-8937
12. Zhao BS, Liu SG, Wang TY, et al. Screening of microRNA in patients with esophageal cancer at same tumor node metastasis stage with different prognoses. Asian Pac J Cancer Prev 2013; 14: 139-143
13. Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 2013; 14: 518-528
14. Frescas D, Pagano M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer 2008; 8: 438-449
15. Zhu X, Shen H, Yin X, et al. Mir-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin. Oncogene 2015 [e-pub ahead of print]
16. Sun P, Hu JW, Xiong WJ, et al. Mir-186 regulates glycolysis through Glut1 during the formation of cancer-Associated fibroblasts. Asian Pac J Cancer Prev 2014; 15: 4245-4250
17. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874
18. Guo Y, Chen Z, Zhang L, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008; 68: 26-33
19. Wang N, Zhang CQ, He JH, et al. Mir-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting Fasl, Timp3, and Reck genes in esophageal carcinoma. Dig Dis Sci 2013; 58: 1863-1870
20. Alder H, Taccioli C, Chen H, et al. Dysregulation of Mir-31 and Mir-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis 2012; 33: 1736-1744
21. Yuan X, He J, Sun F, et al. Effects and interactions of miR-577 and TSGA10 in regulating esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2013; 6: 2651-2667
22. Huang SD, Yuan Y, Zhuang CW, et al. microRNA-98 and microRNA-214 post-Transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human esophageal squamous cell carcinoma. Mol Cancer 2012; 11: 51
23. Sun J, Chen Z, Tan X, et al. microRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med Oncol 2013; 30: 411
24. Gong H, Song L, Lin C, et al. Downregulation of miR-138 sustains NF-KappaB activation and promotes lipid raft formation in esophageal squamous cell carcinoma. Clin Cancer Res 2013; 19: 1083-1093
25. Ni Y, Meng L, Wang L, et al. microRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene 2013; 517: 197-204
26. Yokobori T, Suzuki S, Tanaka N, et al. miR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer Zeb1. Cancer Sci 2013; 104: 48-54
27. Sugimura K, Miyata H, Tanaka K, et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 2012; 18: 5144-5153
28. van Kouwenhove M, Kedde M, Agami R. microRNA regulation by RNAbinding proteins and its implications for cancer. Nat Rev Cancer 2011; 11: 644-656
29. Seki R, Okamura T, Koga H, et al. Prognostic significance of the F-box protein SKP2 expression in diffuse large b-cell lymphoma. Am J Hematol 2003; 73: 230-235
30. Voduc D, Nielsen TO, Cheang MC, et al. The combination of high cyclin E and SKP2 expression in breast cancer is associated with a poor prognosis and the basal phenotype. Hum Pathol 2008; 39: 1431-1437
31. Wang Z, Gao D, Fukushima H, et al. SKP2: a novel potential therapeutic target for prostate cancer. Biochim Biophys Acta 2012; 1825: 11-17
32. Rose AE, Wang G, Hanniford D, et al. Clinical relevance of SKP2 alterations in metastatic melanoma. Pigment Cell Melanoma Res 2011; 24: 197-206
33. Fang FM, Chien CY, Li CF, et al. Effect of S-phase kinase-Associated protein 2 expression on distant metastasis and survival in nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2009; 73: 202-207
34. Schuler S, Diersch S, Hamacher R, et al. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. Int J Oncol 2011; 38: 219-225
35. Radke S, Pirkmaier A, Germain D. Differential expression of the F-box proteins SKP2 and SKP2b in breast cancer. Oncogene 2005; 24: 3448-3458
36. Lin HK, Chen Z, Wang G, et al. SKP2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464: 374-379
37. Wang XC, Wu YP, Ye B, et al. Suppression of anoikis by SKP2 amplification and overexpression promotes metastasis of esophageal squamous cell carcinoma. Mol Cancer Res 2009; 7: 12-22